

Orthopedic Devices Market Size & Share Analysis - Growth Trends and Forecast (2026 - 2031)

Industry: Medical Devices & Equipment

URL: <https://www.mordorintelligence.com/industry-reports/global-orthopedic-devices-market-industry>

Orthopedic Devices Market Size and ShareMarket OverviewStudy Period | 2020 - 2031 |

Market Size (2026) | USD 62.89 Billion |

Market Size (2031) | USD 78.89 Billion |

Growth Rate (2026 - 2031) | 4.64 % |

Fastest Growing Market | Asia Pacific |

Largest Market | North America |

Market Concentration | Medium |

Major Players*Disclaimer: Major Players sorted in no particular order

Image © Mordor Intelligence. Reuse requires attribution under CC BY 4.0.

Image © Mordor Intelligence. Reuse requires attribution under CC BY 4.0.

Orthopedic Devices Market Analysis by Mordor IntelligenceThe Orthopedic Devices Market size was valued at USD 59.97 billion in 2025 and is estimated to grow from USD 62.89 billion in 2026 to reach USD 78.89 billion by 2031, at a CAGR of 4.64% during the forecast period (2026-2031).

Population aging, rising osteoarthritis prevalence, and rapid adoption of minimally invasive technologies continue to propel the orthopedic devices market, even as reimbursement pressure and raw-material volatility temper overall momentum. Orthobiologics are expanding at a double-digit rate, ambulatory surgical centers (ASCs) are winning procedure share, and robotics plus three-dimensional (3-D) printing are reshaping procurement dynamics. Simultaneously, Asia Pacific's volume-based procurement is exerting price discipline on premium brands while the European Union's Medical Device Regulation (MDR) elongates time-to-market for new implants. Market leaders therefore seek margin resilience through bundled robotic platforms, supply-chain localization, and data-enabled aftercare services.

Key Report Takeaways* By product type, joint replacement implants accounted for 35.78% of the orthopedic devices market share in 2025; orthobiologics are projected to advance at a 10.22% CAGR through 2031.

* By technology, conventional implants accounted for 47.83% of the orthopedic devices market in 2025, whereas robotic-assisted and navigation systems are projected to post a 9.84% CAGR through 2031.

* By end user, hospitals captured 55.18% of the orthopedic devices market in 2025; however, ASCs are forecasted to expand at an 8.86% CAGR through 2031.

* By geography, North America accounted for 42.64% revenue in 2025, while Asia Pacific is predicted to grow at an 8.76% CAGR through 2031.

Note: Market size and forecast figures in this report are generated using Mordor Intelligence's proprietary estimation framework, updated with the latest available data and insights as of January 2026.

Market Trends and InsightsDrivers Impact Analysis of Orthopedic Devices Market*Driver | (~) % Impact on CAGR Forecast | Geographic Relevance | Impact Timeline |

Aging Global Population & Osteoarthritis Prevalence | +1.2% | Global, high in North America, Europe, Japan | Long term (≥ 4 years) |

Rising Sports Injuries & Trauma Incidents | +0.7% | North America, Europe, growing in APAC cities | Medium term (2-4 years) |

Technological Advancement in Robotic Surgery & 3-D Printing | +1.0% | North America, EU core, APAC tier-1 hospitals | Medium term (2-4 years) | Expansion of Ambulatory Surgical Centers | +0.8% | North America lead, Australia and GCC early uptake | Short term (≤ 2 years) | AI-Enabled Smart Implants & Data-Driven Alignment | +0.5% | North America, Germany, United Kingdom, Korea pilots | Long term (≥ 4 years) | Cost-Effective Domestic Innovation via Asia Volume-Based Procurement | +0.9% | China, India, spillover to MEA and South America | Medium term (2-4 years) | Source: Mordor Intelligence |

Aging Global Population & Osteoarthritis Prevalence The orthopedic devices market benefits structurally from demographic aging. The World Health Organization estimates that by 2030, 1 in 6 people will be 60 years or older, rising to 2.1 billion by 2050.[1]World Health Organization, "Ageing and Health," WHO.int Osteoarthritis already affects 595 million individuals and is increasing at the fastest rate in East Asia and Western Europe.[2]The Lancet, "Global Burden of Disease Study 2021," thelancet.com Japan and South Korea post the steepest per-capita implant demand, yet keep reimbursement ceilings tight, prompting tiered product portfolios. China's elderly population concentrates in tier-1 and tier-2 cities, where private hospitals command premium pricing, while public tenders favor economical domestic implants. Companies that flex their production cost structures to match both channels limit cannibalization and preserve their margins.

Technological Advancement in Robotic Surgery & 3-D PrintingRobotics has shifted from pilot programs to a procurement prerequisite in many high-volume centers. Zimmer Biomet's ROSA Shoulder and Johnson & Johnson's VELYS platforms joined Stryker's Mako and Smith & Nephew's Cori in 2024, broadening indications from knees and hips to shoulders and partials. Hospitals negotiate bundled robot-implant contracts that lock in multiyear volume, anchoring the orthopedic devices market around integrated ecosystems. Meanwhile, 3-D printing progressed from guides to load-bearing implants; 3D Systems secured clearance for a titanium ankle cage with hollow lattice structures that enhance bone ingrowth.[3]3D Systems, "Titanium Ankle Fusion Cage Cleared by FDA," 3dsystems.com Distributed additive manufacturing trims inventory yet requires ISO 13485-graded quality controls at local print hubs.

Expansion of Ambulatory Surgical CentersASCs deliver orthopedic procedures at lower overhead than hospitals and align with bundled-payment incentives. U.S. ASC large-joint volumes jumped from 10,800 in 2020 to 38,600 in 2023 and are on course to reach 30% of knee and hip replacements by 2029. Implant vendors, therefore, package rapid-recovery protocols, remote monitoring, and just-in-time inventory services to win ASC preference. Europe lags behind because facility licensing is stricter; however, private-equity-backed networks in Spain and the United Kingdom signal an accelerating trend in outpatient uptake.

Cost-Effective Domestic Innovation via Asia Volume-Based ProcurementChina and India implement volume-based procurement rounds, which reduce knee-implant prices by 50-70%, triggering a surge in local manufacturing approvals. In 2024 alone, 23 new Chinese orthopedic device licenses were granted. Domestic firms now export low-cost implants to Africa and Southeast Asia, while multinationals localize production to protect their share. The orthopedic devices market thus bifurcates into price-sensitive high-volume tiers and premium technology segments, compelling global manufacturers to nurture dual portfolios.

Restraints Impact Analysis of Orthopedic Devices Market*Restraint | (~) % Impact on CAGR Forecast | Geographic Relevance | Impact Timeline | High Device Cost & Reimbursement Gaps | -0.9% | Latin America, MEA, South Asia | Short term (≤ 2 years) | Stringent Regulatory Approvals & Product Recalls | -0.6% | North America, EU, emerging in APAC | Medium term (2-4 years) | Critical Raw-Material Bottlenecks (Titanium, PEEK, Ceramics) | -0.5% | Global, pronounced in North America & EU | Short term (≤ 2 years) | Algorithmic Bias & Cyber-Risk Slowing AI-Device Clearances | -0.3% | North America & EU | Long term (≥ 4 years) |

Source: Mordor Intelligence |

High Device Cost & Reimbursement Gaps Out-of-pocket spending in emerging markets still exceeds 40%, making advanced implants unaffordable for a large population segment. Brazil's public system reimburses only BRL 3,000 (approximately USD 600) per knee implant, compared to retail prices of BRL 10,000–15,000 (approximately USD 2,000–3,000). U.S. Medicare reduced total knee arthroplasty payments by 2% in 2025, shifting leverage to group purchasing organizations. Manufacturers respond with stripped-down lines for price-sensitive regions, although gray-market diversion poses a risk to channel conflict.

Stringent Regulatory Approvals & Product Recalls The MDR backlog extends European launch cycles by 12–24 months, driving some firms to prioritize FDA pathways. High-profile recalls, such as Zimmer Biomet's hip prosthesis in 2024, heighten scrutiny of metallurgy and tribology, increasing litigation exposure and surgeon caution. Smaller companies strain under compliance costs, hastening consolidation.

*Our forecasts treat driver/restraint impacts as directional, not additive. The impact forecasts reflect baseline growth, mix effects, and variable interactions

Orthopedic Devices Market Segment Analysis By Product Type: Orthobiologics Accelerate Revenue Mix Shift Orthobiologics outpace the broader orthopedic devices market with a 10.22% CAGR through 2031, gaining traction in spinal fusion and trauma grafting. Joint replacement implants still accounted for the largest share of the orthopedic devices market size at 35.78% in 2025; however, their growth is moderating as mature geographies plateau and price pressure intensifies. Knee implants dominate the market due to the prevalence of osteoarthritis, while reverse total shoulder systems increase the share of the shoulder segment. Manufacturers are pivoting toward ceramic-on-polyethylene bearings in hips to address past concerns with metal-on-metal bearings. Ankle arthroplasty remains a niche procedure, but it is gaining traction thanks to additive-manufactured patient-specific components, such as Paragon 28's APEX 3D cage.

Surgeons increasingly pair demineralized bone matrix with synthetic substitutes to minimize harvest-site morbidity, thereby amplifying the penetration of orthobiologics. Trauma fixation, fuelled by motorcycle injuries in Asia and sports accidents in North America, adds steady volume, though hospitals bargain aggressively on commodity screws and plates. Spinal implants are categorized into fusion cages and motion-preserving discs, with younger patients generally opting for the latter. Sports-medicine devices, especially bioabsorbable anchors, are riding the trend of active aging. Collectively, these shifts redistribute the orthopedic devices market share toward biologics and high-margin soft-tissue solutions.

Image © Mordor Intelligence. Reuse requires attribution under CC BY 4.0. By Technology: Robotics and 3-D Printing Challenge Conventional Dominance Conventional implants held 47.83% of orthopedic devices market share in 2025, but robotic-assisted systems are advancing at a 9.84% CAGR, spurred by hospitals seeking reproducible alignment and shorter length-of-stay. A single Mako installation can lock a facility into USD 1 million of proprietary hardware and consistent implant volume over its lifecycle. Three-dimensional printing moves production closer to the point of care, trimming inventory yet placing ISO 13485 compliance obligations on distributed print farms. As additive builds replicate lattice architectures that foster osseointegration, patient-specific load-bearing implants transition from pilot to routine use, expanding orthopedic devices market size for personalized care.

Sensor-enabled implants, such as Zimmer Biomet's Persona IQ knee, transmit real-time load data, positioning connected devices for long-term monitoring. Payers remain skeptical of the cost-outcome differential, and cybersecurity mandates add

expense, yet early adopters cite reduced revision anxiety. AI-driven planning tools face regulatory headwinds in bias validation, which extends clearance timelines but holds promise for future workflow automation. Conventional implants are expected to retain their market share through 2031; however, their relative contribution to the orthopedic devices market growth will diminish as data-rich platforms garner premium reimbursement.

By End User: ASCs Capture Volume from Hospitals Hospitals captured 55.18% of the orthopedic devices market size in 2025, but ASCs expand at an 8.86% CAGR by delivering same-day discharge and bundled-payment efficiency. Vendor-managed inventory and rapid-recovery protocols resonate with ASC operators that seek to minimize working capital and OR turnover times. Specialty clinics, often physician-owned, cherry-pick elective shoulder and sports-medicine procedures, negotiating direct discounts that undercut hospital purchasing groups. Remote monitoring tools are now integrated with post-operative rehab apps, allowing home settings to enter the orthopedic devices market ecosystem for prolonged care.

Despite erosion, hospitals still anchor complex trauma and revision surgeries owing to intensive care capabilities. Yet payer policy pushes primary large-joint replacements into outpatient pathways, obliging device makers to tailor packaging, automation, and digital follow-up for speed and predictability. This re-balancing of care sites diversifies orthopedic devices market revenue streams and demands supply-chain agility.

Image © Mordor Intelligence. Reuse requires attribution under CC BY 4.0.

Geography Analysis North America Orthopedic Devices Market North America generated 42.64% of the global revenue in 2025 and remains the most significant contributor to the orthopedic devices market in terms of value. Medicare's 2025 2% payment cut for total knee arthroplasty tightened hospital margins, prompting faster migration to ASCs and sharpening negotiations with suppliers. Canada's single-payer model caps implant prices and lengthens waitlists, while Mexico builds medical tourism hubs that lure U.S. patients seeking cost relief.

Broader European Markets Europe is shaped by MDR bottlenecks that delay new launches and amplify compliance costs, particularly in Germany, the continent's largest market. The United Kingdom's National Health Service limits uptake of premium robotics pending conclusive cost-effectiveness data. Southern Europe's fiscal constraints hinder capital budgets, even as private insurers in Spain and Italy expand coverage. Eastern Europe is pressing for affordable conventional implants, whereas Nordic countries are investing in digital health infrastructure, integrating remote monitoring into joint-replacement pathways.

APAC, MEA and South America Orthopedic Devices Market Asia Pacific is the fastest-growing geography, with an 8.76% CAGR through 2031, driven by China's volume-based tenders and India's expanding middle class, along with streamlining at the CDSCO. Japan's aging demographic sustains demand for hip and knee replacements despite stringent domestic trial requirements, while Australia's Therapeutic Goods Administration mirrors FDA standards, serving as a test launch pad. South Korea channels public grants into AI-guided surgery pilots. The Middle East and Africa register uneven progress, with Gulf Cooperation Council nations investing in world-class orthopedics, South Africa balancing a public-private split, and the remainder of the region constrained by reimbursement gaps. South America sees Brazil driving volume but battling affordability, whereas Colombia and Chile gain from insurance penetration. Together, these developments redistribute the orthopedic devices market share toward high-population, value-oriented buyers.

Image © Mordor Intelligence. Reuse requires attribution under CC BY 4.0.

Regulatory Landscape Orthopedic devices are regulated as medical devices, with market access shaped by premarket clearance or approval, along with ongoing quality-system and post-market obligations. In the United States, the FDA oversight framework (including 510(k) pathways for many Class II orthopedic implants and instruments) continues to anchor global launch sequencing, while the Quality Management System Regulation (QMSR) took effect in February 2026, aligning quality-system expectations more closely with ISO 13485-style requirements and increasing documentation and audit-readiness needs for implant and instrument manufacturers.

Classification updates in 2026 also created clearer regulatory pathways for selected orthopedic categories. On June 5, 2026, the FDA finalized Class II classification for absorbable metallic bone fixation fasteners (21 CFR 888.3041). Alongside device regulation, trade policy has emerged as a parallel constraint on sourcing and pricing in orthopedic supply chains, with U.S. tariff-related actions under Section 301 attracting advocacy attention in mid-2026 and adding uncertainty for import-dependent OEMs and their contract-manufacturing networks, particularly for titanium, PEEK, and precision-machined components sourced globally.

Competitive Landscape

The orthopedic devices market remains moderately concentrated, while regional specialists and agile disruptors fill technology and geographic niches. Stryker's Mako ecosystem boosts per-case implant volume, anchoring loyalty and creating regulatory scrutiny over bundled contracts. Zimmer Biomet leverages smart-implant telemetry to differentiate follow-up care; Johnson & Johnson integrates imaging, navigation, and trauma plating under its VELYS suite. Smith & Nephew focuses on mid-tier hospital adoption of Cori robotics, and Medtronic broadens its AiBLE spine platform.

Acquisitions underscore the race for scale and capability. Globus Medical's 2023 merger with NuVasive combined complementary spine portfolios and robotics, reflecting a playbook where mid-tier firms consolidate to fund research and development (R&D) and fulfill global regulatory obligations. Asian manufacturers utilize volume-based procurement to establish a domestic scale, then export cost-optimized implants, challenging incumbents in emerging regions. Orthobiologics and trauma fixation attract venture capital due to their lower capital intensity and faster regulatory pathways, enabling companies such as SeaSpine and Orthofix to specialize without directly confronting large-joint giants.

Intellectual property filings in sensor-embedded hardware and AI software continue to accelerate, but the FDA's 2024 algorithm-bias guidance has extended approval cycles, favoring corporations with seasoned regulatory teams. Quality-management system certifications, especially ISO 13485 audits under MDR, present cost barriers that hasten further consolidation as smaller entities seek shelter within larger portfolios. As competitive stakes shift to technology ecosystems rather than standalone implants, platform breadth and data integration will define future leadership.

Orthopedic Devices Industry Leaders* Smith & Nephew PLC

* Zimmer Biomet

* Stryker Corporation

* Johnson & Johnson Inc

* Medtronic

* *Disclaimer: Major Players sorted in no particular order

Image © Mordor Intelligence. Reuse requires attribution under CC BY 4.0. Orthopedic Devices Market Companies Covered in this Report* Arthrex

* B. Braun Melsungen AG (Aesculap)

* Conmed

* Enovis (formerly DJO Global)

* Exactech

* Globus Medical (NuVasive Inc.)

* Integra LifeSciences

* Johnson & Johnson

* LimaCorporate

* Medtronic

* MicroPort Orthopedics

* Orthofix

* Ossur

* Paragon 28

* Seaspine

* Smiths Group

* Spineart

* Stryker

* Wright Medical Group

* Zimmer Biomet

Market Opportunities and Future Outlook

Lower regulatory friction in select bone-healing and fixation adjacencies is creating whitespace for companies that can package non-invasive therapy and implantable solutions under scalable clearance routes. In April 2026, the FDA issued a final order reclassifying non-invasive bone growth stimulators (product codes L0F and LPQ) from Class III to Class II, shifting commercialization toward the 510(k) pathway and supporting faster product iteration and line extensions for firms active across orthobiologics, bone healing, and adjacent post-op protocols.

Enabling-technology ecosystems and extremities innovation remain active differentiation areas as procedure settings diversify and hospitals standardize on reproducible workflows. DePuy Synthes announced U.S. commercial availability of VELYS Hip Navigation with AI Assistance in June 2026, reinforcing the opportunity for CT-free, software-led intraoperative consistency tied to implant portfolios. Extremities and limb reconstruction niches are also seeing targeted launches, including Paragon 28s SPIDER MONKEY TTT Bone Transport System (June 2026) and Stryker's European rollout of the Pangea Plating System (May 2026, first case at St. George's University Hospital, London), which point to demand for specialized plating, osteotomy, and reconstruction offerings supported by surgeon training, instrumentation logistics, and outpatient-friendly procedural pathways.

Recent Industry Developments in Orthopedic Devices Market* July 2026: Paragon 28 announced the U.S. commercial launch of its SPIDER MONKEY TTT Bone Transport System for transverse tibial transport procedures. The launch expands the company's limb reconstruction toolkit beyond conventional extremities implants, targeting a complex procedural niche that demands specialized instrumentation and surgeon training.

* March 2025: Stryker introduced the fourth-generation Mako 4 SmartRobotics system at AAOS 2025, supporting hip, knee, partial knee, and spine procedures, with over 1.5 million global cases. The update strengthens Stryker's ability to bundle capital equipment with implants and services under multiyear purchasing agreements, reinforcing platform stickiness as hospitals and ASCs standardize workflows.

* August 2024: DePuy Synthes (Johnson & Johnson) released the TriLEAP system, adding low-profile titanium plates for forefoot, midfoot, and hindfoot trauma and

reconstruction. Broadening the extremities portfolio supports share gains in higher-mix foot and ankle procedures, where specialized plating and instrument sets can drive pull-through across hospital and outpatient channels.

Table of Contents for Orthopedic Devices Industry Report1. Introduction

- * 1.1 Study Assumptions & Market Definition

- * 1.2 Scope of the Study

- 2. Research Methodology

- 3. Executive Summary

- 4. Market Landscape

- * 4.1 Market Overview

- * 4.2 Market Drivers* 4.2.1 Aging Global Population & Osteoarthritis Prevalence

- * 4.2.2 Rising Sports Injuries & Trauma Incidents

- * 4.2.3 Technological Advancement in Robotic Surgery & 3-D Printing

- * 4.2.4 Expansion of Ambulatory Surgical Centers

- * 4.2.5 AI-Enabled Smart Implants & Data-Driven Alignment

- * 4.2.6 Cost-Effective Domestic Innovation Via Asia Volume-Based Procurement

- * 4.3 Market Restraints* 4.3.1 High Device Cost & Reimbursement Gaps

- * 4.3.2 Stringent Regulatory Approvals & Product Recalls

- * 4.3.3 Critical Raw-Material Bottlenecks (Titanium, PEEK, Ceramics)

- * 4.3.4 Algorithmic Bias & Cyber-Risk Slowing AI-Device Clearances

- * 4.4 Regulatory Landscape

- * 4.5 Technological Outlook

- * 4.6 Porter's Five Forces Analysis* 4.6.1 Threat of New Entrants

- * 4.6.2 Bargaining Power of Buyers

- * 4.6.3 Bargaining Power of Suppliers

- * 4.6.4 Threat of Substitutes

- * 4.6.5 Competitive Rivalry

- 5. Market Size & Growth Forecasts

- * 5.1 By Product Type* 5.1.1 Joint Replacement Implants

- * 5.1.1.1 Knee Implants

- * 5.1.1.2 Hip Implants

- * 5.1.1.3 Shoulder Implants

- * 5.1.1.4 Ankle Implants

- * 5.1.2 Spinal Implants

- * 5.1.2.1 Fusion Devices

- * 5.1.2.2 Non-fusion Devices

- * 5.1.3 Trauma Fixation Devices

- * 5.1.3.1 Plates & Screws

- * 5.1.3.2 Intramedullary Nails

- * 5.1.3.3 External Fixators

- * 5.1.4 Sports Medicine Devices

- * 5.1.4.1 Arthroscopy Devices

- * 5.1.4.2 Soft-Tissue Repair Implants

- * 5.1.5 Orthobiologics

- * 5.1.5.1 Demineralized Bone Matrix

- * 5.1.5.2 Synthetic Bone Substitutes

- * 5.1.5.3 Stem-Cell Therapy Products

- * 5.1.6 Other Product Type

- * 5.2 By Technology* 5.2.1 Conventional Implants

- * 5.2.2 3-D Printed Patient-specific Implants

- * 5.2.3 Robotic-Assisted & Navigation Systems
- * 5.2.4 Smart Sensor-Enabled Implants
- * 5.2.5 AI-Driven Planning & Measurement Tools

- * 5.3 By End User* 5.3.1 Hospitals
- * 5.3.2 Ambulatory Surgical Centers
- * 5.3.3 Specialty Orthopedic Clinics
- * 5.3.4 Home & Rehabilitation Settings

- * 5.4 By Geography* 5.4.1 North America
- * 5.4.1.1 United States
- * 5.4.1.2 Canada
- * 5.4.1.3 Mexico
- * 5.4.2 Europe
- * 5.4.2.1 Germany
- * 5.4.2.2 United Kingdom
- * 5.4.2.3 France
- * 5.4.2.4 Italy
- * 5.4.2.5 Spain
- * 5.4.2.6 Rest of Europe
- * 5.4.3 Asia-Pacific
- * 5.4.3.1 China
- * 5.4.3.2 Japan
- * 5.4.3.3 India
- * 5.4.3.4 Australia
- * 5.4.3.5 South Korea
- * 5.4.3.6 Rest of Asia-Pacific
- * 5.4.4 Middle East & Africa
- * 5.4.4.1 GCC
- * 5.4.4.2 South Africa
- * 5.4.4.3 Rest of Middle East & Africa
- * 5.4.5 South America
- * 5.4.5.1 Brazil
- * 5.4.5.2 Argentina
- * 5.4.5.3 Rest of South America

6. Competitive Landscape

- * 6.1 Market Concentration
- * 6.2 Market Share Analysis
- * 6.3 Company Profiles (includes Global Level Overview, Market Level Overview, Core Segments, Financials as Available, Strategic Information, Market Rank/Share for Key Companies, Products & Services, and Recent Developments)* 6.3.1 Arthrex Inc.
- * 6.3.2 B. Braun Melsungen AG (Aesculap)
- * 6.3.3 Conmed Corporation
- * 6.3.4 Enovis (formerly DJO Global)
- * 6.3.5 Exactech
- * 6.3.6 Globus Medical (NuVasive Inc.)
- * 6.3.7 Integra LifeSciences
- * 6.3.8 Johnson & Johnson (DePuy Synthes)
- * 6.3.9 LimaCorporate
- * 6.3.10 Medtronic
- * 6.3.11 MicroPort Orthopedics
- * 6.3.12 Orthofix Medical Inc.
- * 6.3.13 Ossur
- * 6.3.14 Paragon 28
- * 6.3.15 SeaSpine
- * 6.3.16 Smith & Nephew plc
- * 6.3.17 Spineart SA
- * 6.3.18 Stryker Corporation
- * 6.3.19 Wright Medical

* 6.3.20 Zimmer Biomet Holdings Inc.

7. Market Opportunities & Future Outlook

* 7.1 White-space & Unmet-Need Assessment

Orthopedic Devices Market Report Scope and Research Methodology
Market Definition and Coverage
This market covers revenues from medical devices used to repair, replace, or stabilize the musculoskeletal system, mainly around joints, bones, and related soft tissue structures, across hospital and ambulatory procedure settings worldwide.

Scope exclusions: External mobility aids and non-procedure rehabilitation products (such as crutches, walkers, and generic supports) are excluded.

Segments Covered in This Report* By Product Type* Joint Replacement Implants* Knee Implants

- * Hip Implants
- * Shoulder Implants
- * Ankle Implants

- * Spinal Implants* Fusion Devices
- * Non-fusion Devices

- * Trauma Fixation Devices* Plates & Screws
- * Intramedullary Nails
- * External Fixators

- * Sports Medicine Devices* Arthroscopy Devices
- * Soft-Tissue Repair Implants

- * Orthobiologics* Demineralized Bone Matrix
- * Synthetic Bone Substitutes
- * Stem-Cell Therapy Products

* Other Product Type

- * By Technology* Conventional Implants
- * 3-D Printed Patient-specific Implants
- * Robotic-Assisted & Navigation Systems
- * Smart Sensor-Enabled Implants
- * AI-Driven Planning & Measurement Tools

- * By End User* Hospitals
- * Ambulatory Surgical Centers
- * Specialty Orthopedic Clinics
- * Home & Rehabilitation Settings

- * By Geography* North America* United States
- * Canada
- * Mexico

- * Europe* Germany
- * United Kingdom
- * France
- * Italy
- * Spain
- * Rest of Europe

- * Asia-Pacific* China

- * Japan
- * India
- * Australia
- * South Korea
- * Rest of Asia-Pacific
- * Middle East & Africa* GCC
- * South Africa
- * Rest of Middle East & Africa
- * South America* Brazil
- * Argentina
- * Rest of South America

Data Sources, Market Sizing, and ValidationDesk Research

Desk research starts by building the demand and supply context for orthopedic procedures and device use, then mapping that activity to device categories that generate revenue. We use public health and utilization signals such as procedure volumes, aging indicators, and injury burden so the market is not sized from a single vendor, and not tied to one geography.

Common inputs include sources such as the World Health Organization for population aging and disease burden context, the OECD and national health ministries for procedure and hospital activity statistics, and the US FDA for device clearances and safety communications that can explain mix shifts. We also use sources such as the US CDC for injury and arthritis related prevalence signals, plus customs and trade statistics portals where available to sanity check import dependence for large implant categories. Company filings, investor presentations, and reputable press help validate product mix direction and pricing commentary, and we selectively use paid subscriptions for company financials and intelligence, news and financials, patent databases, and shipment-level trade databases where it improves consistency. These examples are not exhaustive, and many other public and paid sources were also used for collection, cross-checking, and clarification.

Primary Interviews and Surveys

Primary work is used to test what desk data cannot fully explain, especially the split between procedure growth and price or mix effects. We speak with manufacturers, distributors, surgeons, procurement teams, and hospital administrators across major regions so assumptions on volumes, revisions, and average selling prices can be checked and, where needed, adjusted.

Distribution of primary research fieldwork respondents

Company type | Respondent position | Region |
 Top tier: 30% | CXOs: 14% | APAC: 51% |
 Mid tier: 48% | Functional/Unit leaders: 36% | EMEA: 29% |
 Smaller Players: 22% | Managers: 50% | Americas: 20% |

Market-Sizing & ForecastingThe core sizing logic uses both top-down and bottom-up checks. Procedure demand and installed clinical capacity are reconstructed by geography first, then translated into device revenue pools. For example, joint replacement and trauma fixation volumes, together with typical device usage per procedure, are used to build an addressable demand pool before pricing is applied.

Key inputs include joint reconstruction and revision procedure trends, trauma case volumes, spine and arthroscopy utilization direction, average implant selling prices by major category, and the shift in care settings between hospitals and ambulatory surgical centers. Where public procedure counts are incomplete, gaps are handled using proxy indicators such as orthopedic admissions, surgeon capacity

ty, and payer coverage signals, followed by expert checks to keep implied growth realistic.

Forecasting runs through a scenario analysis anchored on procedure growth and pricing or mix movement, with sensitivity applied for changes such as elective surgery backlogs clearing, reimbursement pressure, and adoption of enabling technologies. The forward view is finalized only after cross-checking sampled supplier roll-ups and channel feedback, so totals remain aligned with what participants see in their day-to-day work.

Data Validation & Update CycleOutputs are validated through several passes that compare modeled revenue against independent signals, including procedure trajectories, device category mix, and region-level growth patterns. When a country shows a sharp jump that is not supported by procedure or pricing signals, the assumptions are rechecked and follow-up calls are triggered to confirm whether it is a real change or a data artifact.

Before sign-off, the model is reviewed by another analyst to confirm that definitions, currency handling, and year alignment are consistent across regions, and then the narrative is checked to ensure it matches the numbers. Reports are refreshed annually, and interim updates are made when material events shift demand or pricing, followed by a final pre-delivery pass so clients receive the most current view.

Mordor Intelligence's Global Orthopedic Devices Market Market Size Compared Against Other Published EstimatesPublished market sizes for orthopedic devices often vary because each publisher draws the line differently on what counts as a device sale and how procedures get converted into revenue. Differences also come from the year used as the anchor point, currency timing, and how quickly prices are assumed to move across implants versus enabling tools.

Braces and other external supports sit outside Mordor Intelligence's scope, which can widen the gap versus estimates that bundle orthopedic consumables and mobility aids into the same revenue pool. We also see spreads when one estimate assumes faster average selling price expansion for premium implants without validating it against procurement feedback, and when regional procedure growth is applied evenly even though elective backlogs and reimbursement pressures differ by geography.

Benchmark comparison

Source | Market Size | Gaps in Research Methodology |
Mordor Intelligence | USD 59.97 B (2025) | |
Global Consultancy A | USD 65.28 B (2025) | Often presented as a broader orthopedic revenue pool, and it can include adjacent categories beyond procedure-linked implant and surgical device sales, which lifts the 2025 total. |
Trade Journal B | USD 64.90 B (2025) | Reported as worldwide orthopedic sales, which may reflect company-reported sales aggregation and wider product baskets, with less transparency on exclusions and currency timing. |
The table shows that most of the spread is explained by scope differences and by how sales are aggregated, rather than by a disagreement on underlying orthopedic procedure demand. By keeping inputs tied to clear procedure and pricing drivers, and then checking them with expert feedback, the resulting estimate stays traceable and repeatable for planning.

Key Questions Answered in the ReportWhat is the current value of the orthopedic devices market? The orthopedic devices market size stood at USD 62.89 billion in 2026 and is projected to reach USD 78.89 billion by 2031.

Which product segment is expanding fastest? Orthobiologics are growing at a 10.2

2% CAGR, more than double the overall market pace.

How are ambulatory surgical centers influencing demand? ASCs are expected to capture 30% of U.S. large-joint procedures by 2029 thanks to lower overhead and bundled-payment alignment.

Which region will add the most new procedure volume? Asia Pacific, led by China and India, is forecast to grow at an 8.76% CAGR as volume-based procurement accelerates implant adoption.

What technology trend is most disruptive? Robotic-assisted surgery is reshaping procurement, with systems such as Mako and VELYS driving a 9.84% CAGR in the robotics segment.

Related Reports Explore More Reports Find Latest Data onCast Saw Devices MarketCompression Therapy IndustryDiathermy Equipment MarketReport on Medical Devices IndustryWearable Medical Devices Industry OverviewOrthopedic Power Tools IndustryOrthopedic Prosthetics Industry OverviewOrthopedic Regenerative Surgical Products IndustryOrthopedic Splints Industry OverviewSmall Bone and Joint Orthopedic Devices IndustryTonsil and Adenoid Removal Products Industry